Právní předpis byl sestaven k datu 19.09.2014.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
SDĚLENÍ
Xxxxxxxxxxxx zahraničních xxxx,
xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 58/2007 Xx. x. s. x x. 46/2008 Xx. x. x. a xxxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx xxxx x. 97/2012 Xx. x. x. o Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, že dne 12. listopadu 2012 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx xxxxx a xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx xxxxxx1).
X xxxxx xxxxxx Xxxxxxx I xxxxxxxx souhlas Xxxxxxxxx Xxxxx republiky.
Xxxx xxxxx Přílohy I xxxxxxxxx x xxxxxxxx x xxxxxxx s xxxxxxx 34 odst. 3 Xxxxxx xxx 1. ledna 2013 x xxxxx dnem xxxxxxxxx x xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxx znění Xxxxxxx X v xxxxxxxx xxxxxxxx xxxxxx znění Xxxxxxx X Xxxxxxxxxxx xxxxxx xxxxx dopingu xx sportu xxxxxx xx 1. xxxxx 2012 x vyhlášené xxx č. 97/2012 Sb. m. s.
Xxxxxxxx xxxxx Přílohy I x xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx současně.
1) Xxxxxxxxxxx xxxxxx proti xxxxxxx xx xxxxxx xxxxxxx xxx 19. xxxxx 2005 v Xxxxxx xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
XXXXXXX I
XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2013
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx od 1. xxxxx 2013
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx kodexu xxxxxxx Xxxxxxxx látky budou xxxxxxxxxx xx "Specifické xxxxx" xxxxx xxxxx xx skupin S1, X2, X4.4, X4.5 x X6(x) x Xxxxxxxxxx xxxxx X1, X2 x X3.
| &xxxx;
XXXXX X XXXXXX XXXXXXXX XXXXX
(PŘI XXXXXXX X XXXX XXXXXX)
|
XXXXXXXX LÁTKY
X0. XXXXXXXXXXX XXXXX
Jakákoliv xxxxxxxxxxxxx xxxxx, která xxxx xxxxxxxx v xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (např. xxxxxx x preklinickém xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx po xxxxxxxx xxxxxxxxxx, syntetické drogy, xxxxxxxxxxx xxxx), je xxxxxxxx xxxxx.
S1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
1. XXXXXXXXXX ANABOLICKÉ XXXXXXXX (XXX):
(a) Xxxxxxxx* AAS, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; boldenon; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); desoxymethyltestosteron (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9,11-trien-3-on); xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; norethandrolon; norklostebol; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-homo-pregna-4,9,11-trien-17β-ol-3-on); xxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(b) Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), androstendion (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-hydroxyandrost-5-en-17-one), xxxxxxxxxxx x jejich xxxxxxxxxx x isomery, xxx xx x xxxxxxxx pouze xx xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (androst-5-en-3,17-dion)
|
|
5α-androstan-3α,17β-diol
|
|
|
5α-androstan-3β,17α-diol
|
epi-dihydrotestosteron
|
|
5α-androstan-3β,17β-diol
|
epitestosteron
|
|
androst-4-en-3α,17α-diol
|
3α-hydroxy-5αandrostan-17-on
|
|
androst-4-en-3α,17β-diol
|
3β-hydroxy-5αandrostan-17-on
|
|
androst-5-en-3β,17α-diol
|
7α-hydroxy-DHEA
|
|
androst-5-en-3α,17α-diol
|
7β-hydroxy-DHEA
|
|
androst-5-en-3α,17β-dioI
|
7-keto-DHEA
|
|
androst-5-en-3β,17α-diol
|
19-norandrosteron
|
|
4-androstendiol (xxxxxxx-4-xx-3β,17β-xxxx)
|
&xxxx;
19-xxxxxxxxxxxxxxxxx
|
2. Ostatní xxxxxxxxxx xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx s omezením xxxxx na ně.
|
Pro xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx vztahuje k xxxxx, kterou tělo xxxx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x látce, xxxxxx xxxx tělo xxxxxxxxxx xxxxxxxxx.
|
X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX A XXXXXXXX XXXXX
Následující xxxxx x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:
1. Látky xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (EPO), darbepoetin (xXXX), stabilizátory xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx hormon (XX) x xxxx;
3. Xxxxxxxxxxxxxx;
4. Xxxxxxx xxxxxx (XX), xxxxxxxxxxxxx xxxxxxx faktory (FGFs), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), insulinu xxxxxxx xxxxxxx faktor-1 (XXX-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), růstový faktor xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF) x xxxxxxxxxx-xxxxxxxxxxxx růstový faktor (XXXX), stejně jako xxxxxxxxx jiné xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx bílkovin xxxxx, šlach x xxxxxx, xxxxxx zásobení, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx nebo ovlivňující xxxx svalových vláken;
x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X3. XXXX2- XXXXXXXX
Všichni xxxx-2 xxxxxxxx včetně xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x x-), xxxx xxxxxxxx kromě salbutamolu (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) x salmeterolu xxxxx jsou xxxxxx x inhalaci x xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx výrobce.
Xxxxxxxxxx xxxxxxxxxxx v xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx vyšší xxx 40 ng/ml xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx použití, xxx bude xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, pokud sportovec xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, že xxxxxxxxxx xxxxxxxx xxx způsoben xxxxxxxx terapeutické xxxxxxxxx xxxxx xxxxx než xxxx xxxxxxx xxxxxxx.
X4. XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, zahrnující:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx ne s xxxxxxxx xxxxx na xx.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), zahrnující:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
3. Ostatní antiestrogenní xxxxx xxxxxxxxxx:
Cyklofenil, xxxxxxxxxxx, klomifen, ale xx x xxxxxxxx xxxxx na ně.
4. Látky xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, ale xx s xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx modulátory:
x) Insuliny;
x) Xxxxxxxx delta aktivovaný xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) agonists/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx aktivované XXX x xxxxxxxxxxx x XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (XXXX) xxxx agonists/ (xxxx. XXXXX)
S5. XXXXXXXXX X OSTATNÍ XXXXXXXXX XXXXX
Maskovací xxxxx xxxx xxxxxxxx. Zahrnují:
Xxxxxxxxx, xxxxxxxxxxxx, plasmaexpandery (xxxx. glycerol, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x další xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx není xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, amilorid, bumetanid, xxxxxxxxx, xxxxxxxxxxxx, indapamid, xxxxxxxx, kyselina etakrynová, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx s xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx (kromě xxxxxxxxxxxx, xxxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxxxx a xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).
Pro xxxxxxx (Xxx Xxxxxxx, případně Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxxx, katin, efedrin, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx xxxxx xxxxx x xx, xxxxx xxx byla xxxxxxx xx diuretikum xxxx xxxxx maskovací xxxxx.
XXXXXXXX XXXXXX
M1. XXXXXXXXXX X KRVÍ X XXXXXXXX KOMPONENTAMI
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxx xxxx znovuzavedení xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx krve nebo xxxxxxxxx krvinek a xxx podobných xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.
2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx produkty (např.krevní xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, mikroenkapsulované xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), xxx xx x xxxxxxxx pouze xx xx. Xxxxxxxxxxxx xxxxxxxx zakázána xxxx.
3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx s xxxx xxxx x xxxxxxxx xxxxxxxxxxxx fyzikálními xxxx xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxx, nebo xxxxx x podvod, za xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx xx zakázané. Xx xxxxxxxx záměnu x/xxxx xxxxxx (např. xxxxxxxxxx) moči, xxx xx x omezením xxxxx na xx.
2. Xxxxxxxxxx xxxxxx x/xxxx injekce více xxx 50 xx xx 6 hodin xxxx zakázány kromě xxxxxx legitimně xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx klinických xxxxxxxxxxxxx xxxxx.
X3. XXXXXX XXXXXX
X xxxxxx potenciálu xx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx xxxxxxxxxx xxxxxxx xxxx jejich xxxxxxxx;
2. Xxxxxxx xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx xxxxx;
| &xxxx;
LÁTKY X METODY XXXXXXXX XXX XXXXXXX
|
Xxxxx kategorií X0 xx X5 x X1 xx X3 xxxxxxxxx xxxx xxxx Xxx Soutěži xxxxxxxx x xxxxxxxxxxx skupiny:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx xxxxxx všech xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x x-) jsou xxxxxxxx, x xxxxxxxx xxxxxxxx xxxxxxxxx x případě xxxxxx místního použití x xxxxxxxxxxx zahrnutých xx Monitorovacího xxxxxxxx xxx xxx 2013*.
Xxxxxxxxxxx zahrnují:
(x) Xxxxxxxxxxxx stimulancia:
Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, benzfetamin, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, famprofazon, fendimetrazin, xxxxxxxxx, fenfluramin, fenkamin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (karfedon), furfenorex, xxxxxxxxxxx, kokain, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, mezokarb, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxx xxxxxxxx, xx Xxxxxxxxxxx látkou.
(x) Specifická xxxxxxxxxxx (xxxxxxxx):
Adrenalin**, xxxxx***, xxxxxxx****, xxxxxxxx, etilefrin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, metylefedrin****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, oxilofrin, xxxxxxxxxxxxxxxxxxxx, pemolin, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, tuaminoheptan x xxxxx xxxxx s xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
* Xxxxxxxxxxx xxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, nikotin, xxxxxxxxx, xxxxxxxx) xxxxxx považovány xx Zakázané látky.
** Lokální xxxxxx xxxxxxxxxx (xxxx. xxxxx, xxxx xxxxxxxx) xxxx xxxx xxxxxx společně x xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
*** Xxxxx je zakázaný xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx v 1 xx xxxx.
**** Xxxxxxx x methylefedrin xxxx zakázány při xxxxxxxxxxx vyšší xxx 10 mikrogramů x 1 xx moči.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx jeho xxxxxxxxxxx x xxxx xx xxxxx než 150 mikrogramů xx xxxxxxxx
S7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, diamorfin(heroin), xxxxxxxx a jeho xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.
S8. XXXXXXXXXXX
Přírodní (xxxx. xxxxx, xxxxxx x xxxxxxxxx) nebo syntetický xxxxx9-xxxxxxxxxxxxxxxxxxx (THC) a xxxxxxxxxxxxxx (xxxx. "Spice" /XXX018, XXX073/ x XX-210) xxxx xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Všechny xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.
| &xxxx;
LÁTKY XXXXXXXX X XXXXXXXX XXXXXXXX
|
P1. ALKOHOL
Xxxxxxx (etanol) je xxxxxxxx pouze Xxx Xxxxxxx x následujících xxxxxxxx. Xxxxxxx xx xxxx provádět xxxxxxxx xxxxxxxx x/xxxx rozborem xxxx. Xxxxxxx xxxxxxx xxx porušeni xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx hodnota) xx 0.10 g/l.
∙ Automobilový xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx x parašutismus(FAI)
∙ Xxxxxxxxxxx (XXXX)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (UIM)
X2. XXXX-XXXXXXXXX
Xxxxx není xxxxx xxxxxx, beta-blokátory xxxx xxxxxxxx xxxxx Xxx Xxxxxxx v xxxxxxxxxxxxx sportech.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Billiard (xxxxxxx xxxxxxxxxx) (WCBS)
∙ Xxxx (IGF)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Mimo xxxxxx)
∙ Xxxxxxxx (XXX) - skoky xx lyžích a xxxxxxxxxxx lyžování-skoky a X-xxxxx,x xxxxxxxxx X-xxxxx x "big air"
∙ Střelba (ISSF, XXX) (xxxxxxxx xxxx Xxxx soutěž)
∙ Xxxxx (XXX)
Beta-blokátory xxxxxxxx následující xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, atenolol, xxxxxxxxx, xxxxxxxxxx, bunolol, xxxxxxxxxx, xxxxxxx, karteolol, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx s xxxxxxxx xxxxx xx ně.
Informace
Xxxxxx xxxxxxx x. 98/2013 Sb. x. x. nabyl xxxxxxxxx xxxx 20.12.2013.
Právní xxxxxxx x. 98/2013 Xx. m. x. xxx xxxxxx právním xxxxxxxxx č. 47/2014 Sb. m. s. x xxxxxxxxx xx 20.9.2014.
Znění jednotlivých xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx v xxxxxxxx xxxx aktualizováno, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.